What’s Next In Immunotherapy? Dr. Kim Margolin of Saint John’s Cancer Institute Provides Insight [Video]

June is immunotherapy month. Principal Investigators at Saint John’s Cancer Institute, Kim Margolin, MD, and Przemyslaw Twardowski, MD, discuss immunotherapy developments in clinical trials. Advances in genomic profiling and biomarker discovery are leading towards personalized medicine. Tailoring treatments on individual tumor characteristics, genetic profiles, and immune system status is also becoming more common as advances in research and innovative clinical trials continue.

Learn more on our blog: https://www.saintjohnscancer.org/blog/whats-next-in-immunotherapy/

Chapters:
00:00 – Dr. Margolin provides recent innovations and immunotherapy success.
03:40 – Dr. Twardowski explains his role in geo-cancers, including prostate cancer and those with different histology. Research includes trials that involve PSMA and CD28 in T-cells.
06:05 – Dr. Kim Margolin discusses trials and the approach using cytokines.
12:29 – A new imaging clincal trial is currently underway for various agents, involving ImaginAb Corp., a biotech firm in Inglewood, California.
16:07 – What does the future hold for immunotherapy care?

#immunotherapy #immunotherapymonth #saintjohnscancerinstitute